EGFR and non-small cell lung carcinoma: The EGFR-TKI efficacy of NSCLC patients with no smoking history and miR-183 relative expression level <1.77 before treatment was better than that of NSCLC patients with smoking history and miR-183 relative expression level ≥1.77 before treatment (all P < 0.05).